Moleculin Biotech, Inc.
MBRX
$2.40
-$0.01-0.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -48.13% | -26.80% | -85.53% | -20.41% | -0.59% |
| Total Depreciation and Amortization | -46.40% | -28.57% | -13.85% | -5.43% | -3.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 345.53% | 427.50% | 831.92% | 1,228.32% | 47.16% |
| Change in Net Operating Assets | -47.37% | 140.26% | -111.59% | 426.89% | 988.89% |
| Cash from Operations | -11.85% | 4.72% | 5.17% | 15.02% | 10.63% |
| Capital Expenditure | -- | -- | 100.00% | 100.00% | 89.52% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | 100.00% | 89.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 112.52% | 485.54% | 129.81% | 357.22% | 214.53% |
| Repurchase of Common Stock | 69.23% | 69.23% | 100.00% | 96.55% | -4.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 112.89% | 488.65% | 130.50% | 360.57% | 215.85% |
| Foreign Exchange rate Adjustments | 30.00% | 259.38% | -785.71% | -64.71% | 23.08% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 128.56% | 123.87% | 82.19% | 84.58% | 55.44% |